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Abstract
Purpose 1. To systematically analyse studies comparing survival outcomes between axillary lymph-node dissection (ALND) 
and axilla observation (Obs), in women with low-risk, clinically node-negative breast cancer. 2. To consider results in the 
context of current axillary surgery de-escalation trials and studies.
Methods 9 eligible studies were identified, 6 RCTs and 3 non-randomized studies (4236 women in total). Outcomes assessed: 
overall survival (OS) and disease-free survival (DFS). The logged (ln) hazard ratio (HR) was calculated and used as the 
statistic of interest. Data was grouped by follow-up.
Results Meta-analyses found no significant difference in OS at 5, 10 and 25-years follow-up (5-year ln HR = 0.08, 95% 
CI − 0.09, 0.25, 10-year ln HR =  0.33, 95% CI − 0.07, 0.72, 25-year ln HR = 0.00, 95% CI − 0.18, 0.19). ALND caused 
improvement in DFS at 5-years follow-up (ln HR = 0.16, 95% CI 0.03, 0.29), this was not demonstrated at 10 and 25-years 
follow-up (10-year ln HR = 0.07, 95% CI − 0.09, 0.23, 25-year ln HR = − 0.03, 95% CI − 0.21, 0.16). Studies supporting 
ALND for DFS at 5-years follow-up had greater relative chemotherapy use in the ALND cohort.
Conclusion ALND does not cause a significant improvement in OS in women with clinically node-negative breast cancer. 
ALND may improve DFS in the short term by tailoring a proportion of patients towards chemotherapy. Our evidence sug-
gests that when the administration of systemic therapy is balanced between the two arms, axillary de-escalation studies will 
likely find no difference in OS or DFS.
Keywords Axillary dissection · Axillary clearance · Early breast cancer · Axillary lymph nodes
Introduction
Lack of evidence-based demonstration of survival ben-
efit in landmark trials such as NSABP B-04 [1] and ACO-
SOG Z0011 [2] have been pivotal in reducing the extent of 
surgery in breast cancer. Currently, the SOUND [3] trial 
aims to determine whether there is a therapeutic role in 
sentinel lymph node biopsy (SLNB) over observation alone 
in low-risk breast cancer with normal preoperative axil-
lary imaging. However, studies pre-dating the SLNB era, 
which compared axillary lymph node dissection (ALND) to 
observation (Obs) in clinically node-negative women with 
invasive breast cancer, can shed light on the likely direction 
results, from axillary de-escalation trials, will take. A pre-
vious review by Sanghani et al. [4] conducted a three-way 
comparison between Obs, ALND and axillary radiotherapy 
and reported no differences in survival. The review was lim-
ited to a follow-up of 5-years, and only two (of four) stud-
ies compared axillary ALND to Obs. In this review, studies 
pre-dating SLNB and comparing ALND to Obs only are 
comprehensively assessed and a meta-analysis is conducted 
to examine the difference in long-term outcomes between 
ALND and Obs in women with low-risk, clinically node-
negative breast cancer. Furthermore, the relevance of results 
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The study was conducted in accordance with the Preferred 
Reporting Items of Systematic Reviews and Meta-Analyses 
(PRISMA) guidance.
Search process and study selection
A systematic literature search was conducted using PubMed/
MEDLINE and Cochrane databases. Search terms included: 
breast cancer, node negative, axillary dissection, clearance 
and radical mastectomy. The search, and title and abstract 
screening were conducted by one author (M.S.), full arti-
cle screening was conducted independently by two authors 
(M.S. and M.A.), disagreements in study selection were 
resolved through discussion. Results of each stage are illus-
trated in Fig. 1. Reference lists of screened articles were also 
reviewed. Date of the last search: 15th April 2021.

























Addional records idenfied 
through reference lists 
(n = 23)
Records aer duplicates removed 
(n = 2807) 
Records screened 
(n = 2807) 
Records excluded 
(n = 2766) 
Full-text arcles assessed 
for eligibility 
(n = 41)
Full-text arcles excluded, with 
reasons: 
- Lack of control and/or 
intervenon group (n = 7) 
- Impossible to discern clinically 
node negave group from node 
posive group (n = 4) 
- Absence of data for both OS 
and DFS (n = 7) 
- Substanal involvement of 
SLNB or axillary radiotherapy in 
protocol (n = 14) 
Studies included in 
qualitave synthesis 
(n = 9)
Studies included in 
quantave synthesis 
(meta-analysis) 
(n = 9) 




All studies comparing long-term outcomes between ALND 
and Obs of the axilla in women with clinically node-nega-
tive invasive breast cancer were eligible. Studies must have 
reported at least one measure of long-term outcome that 
could be extracted from text or figures. Measures were pre-
specified as overall survival (OS) and disease-free survival 
(DFS) due to relative consistency in reporting. Studies must 
have been published in the English language. Studies not 
fulfilling the inclusion criteria were excluded, no restrictions 
were placed on study design or year of publication.
Bias assessment
Bias assessment was carried out by two authors (M.S. and 
M.A.) independently, then reviewed jointly for discrepan-
cies and re-assessment. Bias was assessed in accordance 
with the Cochrane Handbook [5]. For randomised control 
trials (RCTs), the ‘revised Cochrane risk of bias tool for 
randomized trials’ (RoB 2) [6] was used. For non-ran-
domised studies, the ‘Risk Of Bias In Non-randomized 
Studies—of Interventions’ (ROBINS-I) tool [7] was used. 
Overall assessment of bias is presented in Fig. 2.
Data collection and statistical analysis
Study data was extracted by one author (M.S.) and reas-
sessed by a second (M.A.) Where available, the following 
variables (presented in Table 1) were collated: total sample 
size, control/intervention sample size, mean/median age, 
follow-up period, OS and DFS at each follow-up interval 
and corresponding hazard ratios (HR), axillary recurrence, 
the proportion of ALND group with involved lymph nodes, 
proportion of cohort with T1 staged disease, proportion with 
oestrogen receptor (ER) positive disease and proportion of 
cohort receiving chemotherapy, radiotherapy and endocrine 
therapy. Where OS and DFS were available from survival 
curves only, the PlotDigitizer [8] software was used to 
extract data.
Fig. 2  Results of bias analyses. 
a Summary table of results 
from RoB 2 bias analysis of 
RCTs. b Summary of results 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Data were analysed by authors R.B. and M.S. An odds 
ratio (OR), as seen in other reviews, was not deemed suitable 
as DFS/OS (cumulative survival data) cannot be reliably 
converted into an OR and no studies reported crude sur-
vival data. There was an additional issue where few stud-
ies reported hazard ratios or standard errors for OS/DFS at 
each interval of follow-up. Instead an approach suggested by 
Moodie et al. [9], for meta-analyses of survival data where 
HR and SE are not reported, was considered appropriate 
and viable after discussion with statistician colleagues. Data 
processing was carried out by author R.B. using Fortran90 
[10]–[12]. Code is presented in supplementary materials and 
utilised data for: OS, DFS and number at risk. A million 
simulations were ran to calculate the HR and SE for each 
study. From this, values for logged (ln) HR, ln SE and 95% 
confidence intervals (CI) for each study were acquired and 
used as the statistics of interest for meta-analyses, results are 
presented in Table 2. Meta-analyses were grouped according 
to follow-up interval (5, 10 and 25-years) and were con-
ducted using RevMan 5.4.1 [13]. A random/fixed-effects 
model was used depending on the presence/absence of het-
erogeneity, respectively [14]. Heterogeneity was evaluated 
using the  Chi2 test [15]. Egger’s Funnel Plot was used to 
assess for publication bias.
Results
Selected studies
2824 studies were identified. The final review found nine 
suitable studies: six RCTs, one non-randomised control trial, 
one retrospective study and one cohort study (Table 1).
Study characteristics
Study characteristics are presented in Table 1. 2617 patients 
were assigned to ALND and 1619 to Obs. OS was defined as 
the interval from randomization to the last point of follow-up 
or death from all causes in all studies. DFS was defined as 
the interval from randomization to death, first recurrence of 
disease in the breast, axilla or elsewhere, or last follow-up 
in all studies.
Risk of bias within and across studies
Bias assessment results are presented in Fig. 2 with indi-
vidual comments in Table 1. Of the six RCTs, four included 
power analyses [16, 19]–[21], none achieved sufficient num-
bers. There were concerns over randomization techniques 
used by three RCTs. Blinding was not feasible in any study. 
Details on withdrawn participants were given in all studies 
and did not impact results. Concerns over censorship and 
missing outcome data were present in one study [16]. One 
study ended patient recruitment early [16] and one extended 
the recruitment window [20]. All studies had some concerns 
over selective reporting of result statistics.
Of the three non-randomized studies, two included small 
sample sizes [17, 22]. One cohort study [18] lacked an 
appropriate method to control for confounding and the study 
design allowed for selection bias. Concerns over bias due 
to measurement outcomes were present in all three studies.
Funnel plots were symmetrical and suggested no publica-
tion bias.
Results of individual studies
The RCT by Agresti et al. [18] compared ALND to Obs 
in women aged 30–65. No significant difference in OS 
(HR = 1.09, 95% confidence interval (CI) 0.59–2.00, 
p = 0.783) and DFS (HR = 1.04, CI 0.56–1.94, p = 0.898) at 
10-years follow-up.
The RCT by Martelli et al. [20] compared ALND to Obs 
in post-menopausal women aged 65–80. No significant 
difference in hazard of death (HR = 1.18, CI 0.73–1.92), 
breast cancer-related mortality (HR = 0.721, CI 0.27–1.89, 
p =  0.51) and distant metastases (HR = 1.572, CI 0.70–3.50, 
p =   0.27) was found at 15-years follow-up.
The RCT by Avril et al. [16] compared ALND to Obs 
in post-menopausal women aged > 50. Significant differ-
ence in OS (HR: 3.07, 90%C I 1.40–6.70, p  = 1) and DFS 
(HR = 2.26, 90% CI 1.32–3.86, p = not reported), was found 
at 5-years follow-up. Our statistical analyses, using the 
study’s data, emulated these findings but did not demonstrate 
significance in either OS or DFS (Figs. 3a and 4a).
The RCT by Rudenstam et al. [21] compared ALND to 
Obs in post-menopausal women. No significant difference in 
OS (HR = 1.05, CI 0.76–1.46, p = 0.77) and DFS (1.06, CI 
0.79–1.42, p = 0.69) was found at 5-years follow-up.
The RCT by Fisher et al. [1] compared radical mastec-
tomy (RM) to mastectomy without axillary radiation (M) 
in pre-, peri- and post-menopausal women. No significant 
difference between RM and M was demonstrated at 25-years 
(HR = 1.03, CI 0.87–1.23, p = 0.72 and HR = 1.10, CI 
0.89–1.35, p =   0.39 for OS and DFS, respectively), 10-years 
(OS: RM vs. M: 58 ± 2.6 vs. 54 ± 2.7, and DFS: RM vs. M: 
47 ± 2.6 vs. 42 ± 2.6) and 5-years follow-up (OS: RM vs. 
M: 75 ± 2.3 vs. 74 ± 2.3 and DFS: RM vs. M: 60 ± 2.5 vs. 
56 ± 2.5).
The RCT by Fentiman et al. [23] compared Halstead 
Mastectomy (HM) to wide local excision (WLE) in women 
aged > 50. The study reported worse survival outcome after a 
mean follow-up of 9-years (HM vs. WLE: 82% vs. 60%) and 
increased loco-regional relapse (8% vs. 30%, respectively).
The non-randomised trial by Shin et al. [17] compared 





































































































































































































































































































































































































































































































































































































































































difference in OS (ALND vs. Obs: 98 vs. 98) and DFS (96 
vs. 93) was found at 5-years follow-up.
The retrospective study by Feigelson et al. [22] compared 
breast surgery with ALND (AS) to lumpectomy only (LO) in 
menopausal women aged 70–95. No significant difference in 
OS (AS vs. LO: 82.8 vs. 85.7) was found. Of note, non-axil-
lary surgical approaches were not balanced between arms.
The cohort study by Bedwani et al. [18] compared radical 
surgeries (RS) to non-radical surgery (NRS) in pre-, intra- 
and post-menopausal women. They found no significant 
difference in DFS (RS vs. NRS: 62.7 vs. 63.2) at 5-years 
follow-up.
Logged Overall Survival Hazard Ratio Meta‑Analysis
At 5-years follow-up there were seven viable studies. Stud-
ies showed no heterogeneity (I2 = 0%, χ2 = 4.41, p = 0.62), 
thus a fixed-effect analysis was used. Meta-analysis for ln 
OS HR showed no significant difference (0.08, CI -0.09, 
0.25; Fig. 3a) between ALND and Obs. Removal of non-
randomised studies resulted in no change in ln HR for OS at 
5-years follow-up (0.08, CI:-0.09, 0.25).
At 10-years, three studies remained. There was significant 
heterogeneity between studies (I2 = 79%, χ2 = 9.63, p = 0.008; 
Fig. 3b), thus a random-effects analysis was used. Meta-anal-
ysis showed no significant difference in OS (0.33, CI − 0.07, 
0.72). The study by Fentiman et al., which strongly opposed 
observation, used comparatively low-dose adjunct therapy, 
which may have contributed to heterogeneity. Removal of 
this study results in a ln HR that is in keeping with 5- and 
25-years follow-up and does not show heterogeneity (0.11, 
CI -0.07 to 0.28, I2 = 0%, χ2 = 0.03, p = 0.86).
Only Fisher et al. produced data for 25-years follow-up 
[1], equivalence in OS ln HR (0.00, CI − 0.18, 0.19) was 
demonstrated.
It appears that data favours equivalence the longer the 
follow-up interval.
Logged disease‑free survival hazard ratio 
meta‑analysis
At 5-years follow-up there were six viable studies. Studies 
showed little heterogeneity (I2 = 11%, χ2 = 5.60, p = 0.35), 
thus a fixed-effect analysis was used. Meta-analysis for DFS 




Fig. 3  Meta-analysis and Forrest Plot for Overall Survival. a 5-year follow-up b 10-year follow-up c 25-year follow-up
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CI 0.03, 0.29; Fig. 4a). Removal of non-randomised stud-
ies results in DFS favouring axillary dissection at 5-years 
follow-up but no longer significant (0.10, CI − 0.05, 0.25).
At 10-years, two studies remained. There was no het-
erogeneity between studies (I2 = 0%, χ2 = 0.21, p = 0.65; 
Fig. 4b), thus a fixed-effect analysis was used. Meta-analy-
sis demonstrated no significant difference between Obs and 
ALND (0.07, CI − 0.09, 0.23).
Only Fisher et al. produced data for 25-years follow-
up, which demonstrated no significant difference in DFS 
(− 0.03, CI − 0.21, 0.16).
As with OS, data from later follow-up intervals favours 
equivalence more so than short-term.
Discussion
Meta-analyses demonstrate that the lack of survival advan-
tage from ALND presented in individual studies was not 
due to a lack of power and was not limited by the age of the 
cohort.
No significant difference in OS at 5, 10 and 25-years 
follow-up was identified between ALND and Obs. DFS 
was significantly greater in the ALND cohort at 5-years 
follow-up, but became non-significant at 10- and 25-years 
follow-up and shifted towards equivalence.
Our findings are supported by a previous study by Sang-
hani et al. [4] which compared axillary radiotherapy, dissec-
tion and observation. Authors found no improvement in OS 
when comparing dissection to radiotherapy (1 study) and 
observation (2) or when comparing radiotherapy to obser-
vation (1). Conversely, the study found no significant dif-
ference in DFS at 5-years, but was limited to a small study 
selection, comparisons between multiple interventions/pro-
tocol and an inappropriate statistical technique [9].
Additionally, we report that non-significant difference 
in survival is sustained over longer follow-up, confirming 
that treatment after recurrence benefits survival in the Obs 
cohort and early recurrence in the Obs cohort does not lead 
to increased reduction in long-term survival. Moreover, stud-
ies analysed in Sanghani et al.’s review were limited to an 
older patient cohort, our findings suggest that ALND does 
not improve survival irrespective of age.
Disease‑free survival
Despite initial significant improvement in DFS in the ALND 




Fig. 4  Meta-analysis and Forrest Plot for Disease-Free Survival. a 5-year follow-up b 10-year follow-up c 25-year follow-up
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treatment, specifically chemotherapy, may explain this result 
as it has been shown to improve survival [24]. We posit that 
ALND identifies the presence of axillary metastases and 
tailors the sub-group towards adjuvant treatment that more 
effectively reduces the rate of recurrence. In the Obs cohort, 
patients who have a relapse of disease undergo ALND and 
are treated with a similar protocol and thus overall survival 
is not impacted in the long-term.
When examining studies individually, four [16, 17, 19, 
21] showed variation in adjuvant therapy between ALND 
and Obs groups and two [1, 18] did not disclose adjuvant 
therapy use. Three studies utilised adjuvant chemotherapy 
in the treatment protocol, all reported greater usage in the 
ALND cohort (Obs vs. ALND: Shin: 3% vs 29%; Avril: 
2% vs 8%; Agresti: 35.5% vs 51.5%). Two studies (Shin 
et al. and Avril et al.) reported greater DFS in ALND over 
Obs, with a large relative difference in chemotherapy usage 
between the two cohorts. However, ln HR was not significant 
in either. The Agresti study had the smallest relative differ-
ence in chemotherapy and DFS is marginally in favour of 
Obs, though not significant.
These findings support the notion that chemotherapy 
may be responsible for improving early DFS by eliminating 
metastatic disease that is conducive to early recurrence, and 
that ALND is able to select for disease that is responsive to 
chemotherapy and which would otherwise recur in a 5-year 
interval.
This may also be true for SLNB. Studies such as the 
Z0011 trial [2] and more recently a study by Shigematsu 
et al. [25] had participants undergo SLNB before assignment 
to Obs or ALND. Both reported no difference in the propor-
tion of participants receiving adjuvant chemotherapy and, as 
expected, no difference in 5-year DFS.
Axillary recurrence
Although ALND appears to select for a disease that benefits 
from chemotherapy, it cannot identify, with a high degree of 
sensitivity, the small cohort of women who have metastases 
that lead to recurrences.
Previous analyses [26] have highlighted increased axillary 
recurrence in the Obs cohort and its lack of association with 
the number of patients with histologically involved nodes in 
the ALND cohort [4]. Although not formally assessed, data 
presented within this study (Table 2) leans towards the sup-
port of this. Our results suggest axillary recurrence in the 
Obs cohort does not correlate with the proportion of patients 
in the ALND group with histologically node-positive dis-
ease, nor with a significant difference in DFS beyond short-
term follow-up.
This finding supports a hypothesis initially proposed by 
Veronesi et al. [27] that postulated the presence of indolent 
metastases that are unlikely to lead to disease recurrence 
and more aggressive metastases that do lead to recurrence.
Genotypic differences in metastases may explain the pres-
ence of a small cohort of women who have aggressive micro-
scopic, metastatic foci that lead to occult recurrence rather 
than remaining indolent. In this group, ALND or SLNB 
may be necessary to reduce disease progression. But, as the 
recurrence cohort is small, this will expose many women 
to unnecessary surgery and a greater risk of comorbidities.
Genomic assays present an alternative and non-invasive 
solution that can identify loci which confer a recurrence risk 
in initially clinically node-negative women. The efficacy of 
genomic assays for this purpose should be investigated in 
future studies.
In the context of modern trials
Current ongoing trials are examining the extent to which 
ALND should be omitted, our review of pre-SLNB studies 
can provide some insight into the expected results of these.
The SENOMAC trial [28] is randomising patients with 
T1-3 primary breast tumours and up to two axillary macro-
metastases to either SLNB only or SLNB with dissection. 
Parallels with our study can be drawn, for instance authors 
argue that previous trials omitted key groups such as those 
who underwent mastectomy and therefore ALND cannot be 
confidently ruled out. All three studies (Shin et al., Fenti-
man et al. and Bedwani et al.), analysed in this review that 
involved mastectomy, supported ALND at 5- and 10-years 
follow-up respectively, suggesting patients undergoing 
mastectomy (who likely have higher grade disease) benefit 
from dissection. It is important to note that the (neo)adju-
vant therapy regimen, which we argue is critical in equating 
survival between cohorts, in these three studies differs from 
the regimens of the modern era. Similarly, SLNB may guide 
no ALND patients towards specific and more intense therapy 
than if the axillary status remained unknown. Therefore no 
difference in survival is an equally plausible result from the 
SENOMAC study.
The SERC trial [29] is examining the value of ALND in 
patients with breast cancer of higher risk features. Currently 
reported underpowered results suggest that chemotherapy 
use significantly reduces the presence of disease in sentinel 
nodes and more so when given prior to dissection. Consid-
ering our results suggest few histologically node-positive 
patients undergo disease recurrence, reducing the burden 
further with chemotherapy prior to ALND/SLNB implies 
that even SLNB may not be needed when neoadjuvant chem-
otherapy is administered in women with breast cancer of 
select characteristics.
Our findings can be extrapolated to suggest that trials 
such as TAXIS [30] and Alliance A011202 [31], which are 
examining the effect of radiotherapy (RT) on the undissected 
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and dissected axilla, will not identify improved survival out-
comes. It is plausible that loco-regional recurrence may be 
reduced by RT in these studies. Therefore, the short-term 
improvement in DFS caused by ALND may be minimised as 
the undissected group will also be receiving targeted axillary 
(radio)therapy which prior studies have established is equiv-
ocal to dissection in the low-risk cohort [32]. This is sup-
ported by that fact that our result of significant improvement 
in DFS at 5-years follow-up differs from similar reviews [33, 
34] that included axillary RT with no surgical intervention 
and found no significant difference in DFS over a similar 
interval.
In the context of the SOUND [3] and INSEMA [35] tri-
als, which are comparing SLNB to Obs in low-risk breast 
cancer, our findings suggest that Obs will unlikely be infe-
rior to SLNB, especially considering the eligible cohort is 
of a lower risk than patients recruited in studies analysed 
by this review.
Qualitative analysis of variables
All studies, excluding Fentiman et al., Feigelson et al., Bed-
wani et al. and Shin et al., provided evidence to support 
balanced patient assignment to surgical procedure. Stud-
ies with unbalanced surgical therapy assignment had more 
extensive non-axillary surgery in the ALND group com-
pared to Obs. There was support for ALND improving OS 
at 10-years follow-up by Fentiman et al. Additionally, there 
was support for ALND improving DFS at 5-years follow-up 
by Bedwani et al. and Shin et al. It is unlikely these studies 
skewed results towards favouring dissection as meta-analysis 
excluding these sub-optimal studies does not alter results 
dramatically. When all other parameters are controlled, it 
is unlikely the primary breast surgery type exacerbates any 
effect ALND has on OS or DFS.
No study reported a significant difference in the pro-
portion of patients with positive oestrogen/progesterone 
receptors between study arms. Two studies reported greater 
endocrine therapy use in the Obs cohort (Shin: 84% vs 70%; 
Avril: 91% vs 66%) and showed increased DFS in ALND 
(non-significant ln HR). One study reported greater endo-
crine therapy usage in the ALND cohort (Agresti: 41% vs 
56%) and favoured Obs for DFS (non-significant). Endocrine 
therapy is unlikely to truly detriment DFS as other reports 
suggest otherwise[36]. Chemotherapy preceded endocrine 
therapy in the Agresti study and was used only in patients 
with poor characteristics; it is likely chemotherapy in the 
Obs cohort positively influenced DFS rather than endocrine 
therapy correlating with DFS decline in the ALND cohort. 
Radiotherapy usage was similar between ALND and Obs 
cohorts and is thus unlikely to influence DFS at 5-years 
follow-up.
Perioperative therapy changed between 1996 and 2014. 
Increasing efficacy of non-surgical therapeutics may tend 
recent studies towards equivalence and historic studies 
towards ALND. This was not demonstrated by our results 
which instead suggested an association with unbalanced 
chemotherapy assignment between arms. Instead recur-
rence rates may have reduced over time as perioperative 
treatment protocols shifted. Due to the lack of complete-
ness of reported data, this could not be assessed.
Limitations and future direction
Our study was limited by the lack of declared values for 
HR (of OS and DFS) and standard error, and variation in 
follow-up periods. This was mitigated through appropriate 
statistical techniques.
Of the studies assessed, a single study by Avril et al., 
which suggested ALND improved both OS and DFS, was 
attenuated when adjusted based on our statistical analy-
sis. This is not concerning, however, as authors reported a 
HR < 1.6 would support equivalence and the lower confi-
dence intervals of declared data for OS and DFS are below 
this value (1.40 and 1.32, respectively). Our statistical 
analyses mirror these findings, showing that Avril et al.’s 
data is in favour of OS and DFS at 5-years follow-up but 
the results are not significant. Of further note, Avril et al. 
also reported a trend towards equivalence from uncensored 
data in all parameters except DFS, which supports our 
analysis.
A single study recorded survival at 25-years follow-up, 
more data is required to confirm equivalent survival over 
extended follow-up.
Future studies should assess the risk of comorbidities 
from SLNB when compared to axillary Obs only, and the 
value of genomic assessment compared to SLNB in strati-
fying patients into those who would benefit from further 
axillary therapy and those who would not.
Qualitative analysis was conducted on pre-specified data. 
Comprehensive and quantitative subgroup analysis was not 
possible due to limited access to raw data, such an analysis 
may yield information on the variation of treatment effect in 
subgroups and should be attempted in future studies.
Non-randomised studies were included in this study 
with the aim to comprehensively analyse all data available 
and generate representative findings. Unfortunately, this 
increased risk of confounding bias. The extent was mini-
mised by strict non-randomised study bias assessment by 
two authors. Moreover, the undue effect from non-ran-
domised studies is unlikely to be substantial, as these stud-
ies were weighted less, and analysis demonstrated equivocal 




The results of this study indicate long-term equivalence 
in OS between ALND and Obs in all women with early-
stage low-risk breast cancer, however, some improvement 
in DFS is seen in the ALND cohort in the short-term. It 
is unlikely difference in OS or DFS will be identified in 
axillary de-escalation studies of clinically node-negative 
breast cancer when the administration of systemic therapy 
is balanced between the two arms. However, the value of 
ALND, and possibly SLNB, may be in its ability to tailor a 
proportion of patients towards chemotherapy and thus DFS 
improvement, but this does not translate to OS benefit as 
relapses are treated by further interventions.
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